Chemomab Therapeutics Announces Key Decisions from Annual Shareholders Meeting

Chemomab Therapeutics ( (CMMB) ) has provided an announcement.

On July 1, 2025, Chemomab Therapeutics held its annual general shareholders meeting where key decisions were made, including the re-election of board members Dr. Nissim Darvish and Ms. Jill Quigley, the approval of a grant of 75,000 restricted share units to CEO Dr. Adi Mor, and the re-appointment of Somekh Chaikin as the independent registered public accounting firm. These decisions reflect the company’s ongoing commitment to strengthening its leadership and ensuring financial oversight as it continues to focus on its strategic goals in the biotech sector.

The most recent analyst rating on (CMMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.

Spark’s Take on CMMB Stock

According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.

Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.

To see Spark’s full report on CMMB stock, click here.

More about Chemomab Therapeutics

Chemomab Therapeutics Ltd. is a biotechnology company based in Tel-Aviv, Israel, focusing on the development of therapeutics for fibrotic and inflammatory diseases. The company is involved in advancing its pipeline of monoclonal antibody treatments targeting chronic and rare conditions.

Average Trading Volume: 141,908

Technical Sentiment Signal: Sell

Current Market Cap: $22.07M

For detailed information about CMMB stock, go to TipRanks’ Stock Analysis page.